Clinical Trial: Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies

U.S., Sept. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07802756) titled 'Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies' on Aug. 31.

Brief Summary: This is an investigator-initiated, single-center, dose-escalation and dose-expansion early-phase clinical study to evaluate the safety and efficacy of iMagic Injection in participants with hematologic malignancies. The study consists of two cohorts: Cohort 1 enrolls participants with relapsed/refractory B-cell non-Hodgkin lymphoma, and Cohort 2 enrolls participants with relapsed/refractory multiple myeloma. Eligible participants in each cohort will receive infusions of iMagic Injection (IMV101 for lymphoma, IMV102 fo...